Milestone Biosciences

Milestone Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. The company's lead product candidate is etripamil, a novel, potent, short-acting calcium channel blocker designed as a rapid-onset, self-administered nasal spray. Etripamil is currently being evaluated in Phase 3 clinical trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in Phase 2 for atrial fibrillation with rapid ventricular rate (AFib-RVR). Milestone aims to empower patients to manage their conditions in the outpatient setting, potentially reducing the need for emergency room visits and providing a more convenient alternative to intravenous treatments.